News
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
The Well-Funded ($50M) Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
SpliSense Secures $28.5 Million in Series B Financing
Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings and the Cystic Fibrosis Foundation participated in the round.
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22
Biond to receive $125 million upfront with more than $1 billion in potential development, regulatory, and sales milestones plus royalty payments for global rights to a novel immune checkpoint inhibitor.